Equities

Stella Pharma Corp

4888:TYO

Stella Pharma Corp

Actions
  • Price (JPY)479.00
  • Today's Change7.00 / 1.48%
  • Shares traded297.60k
  • 1 Year change+61.28%
  • Beta1.9173
Data delayed at least 20 minutes, as of Nov 14 2024 05:16 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments2,3542,7103,276
Total Receivables, Net765917
Total Inventory1,116941774
Prepaid expenses413936
Other current assets, total434372
Total current assets3,6293,7934,175
Property, plant & equipment, net8210392
Goodwill, net------
Intangibles, net536268
Long term investments--303305
Note receivable - long term------
Other long term assets192121
Total assets3,8214,3294,719
LIABILITIES
Accounts payable764949
Accrued expenses4.796.102.16
Notes payable/short-term debt000
Current portion long-term debt/capital leases160160160
Other current liabilities, total21520697
Total current liabilities456422308
Total long term debt7739331,093
Total debt9331,0931,253
Deferred income tax------
Minority interest------
Other liabilities, total215222238
Total liabilities1,4441,5771,639
SHAREHOLDERS EQUITY
Common stock2,9383,3003,808
Additional paid-in capital1962211,908
Retained earnings (accumulated deficit)(757)(769)(2637)
Treasury stock - common(0.03)(0.03)--
Unrealized gain (loss)------
Other equity, total--0.000.00
Total equity2,3772,7533,080
Total liabilities & shareholders' equity3,8214,3294,719
Total common shares outstanding313029
Treasury shares - common primary issue0.000.000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.